[HTML][HTML] Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among …
(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
[PDF][PDF] Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among …
PM Berrino, M Gatti, M Rinaldi, E Brunocilla, P Viale… - 2023 - pdfs.semanticscholar.org
(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic …
PM Berrino, M Gatti, M Rinaldi… - Antibiotics (Basel …, 2023 - pubmed.ncbi.nlm.nih.gov
(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem …
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion piperacillin-tazobactam or meropenem and microbiological outcome among urologic …
PM Berrino, M Gatti, M Rinaldi, E Brunocilla, P Viale… - 2023 - cabidigitallibrary.org
Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem …
[HTML][HTML] Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among …
PM Berrino, M Gatti, M Rinaldi, E Brunocilla, P Viale… - Antibiotics, 2023 - ncbi.nlm.nih.gov
Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic …
P Berrino, M Gatti, M Rinaldi, E Brunocilla… - Antibiotics (Basel …, 2023 - europepmc.org
Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic …
PM Berrino, M Gatti, M Rinaldi, E Brunocilla… - …, 2023 - search.proquest.com
Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic …
PM Berrino, M Gatti, M Rinaldi… - Antibiotics (2079 …, 2023 - search.ebscohost.com
Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic …
PM Berrino, M Gatti, M Rinaldi, E Brunocilla, P Viale… - ANTIBIOTICS, 2023 - cris.unibo.it
:(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin-tazobactam or meropenem …
[PDF][PDF] Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among …
PM Berrino, M Gatti, M Rinaldi, E Brunocilla, P Viale… - 2023 - cris.unibo.it
(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …
(PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem …